[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100286122":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":35,"centralContacts":40,"locations":49,"responsibleParty":74,"collaborators":10,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":10,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":86,"minAge":87,"maxAge":10,"enrollmentInfo":88,"targetDuration":10,"studyType":91,"phases":10,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":52,"whyStopped":10,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","OTHER",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Chronic hemodialysis patients",null,"Patients on standard in-centre 3 times a week hemodialysis",[13],"Other: Measuring sodium content",{"label":15,"type":10,"description":16,"interventionNames":17},"Peritoneal dialysis patients","Patients on peritoneal dialysis",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Adult and paediatric patients with CKD stage 1-5","Patients with chronic kidney disease stage 1-5 (not dialysis dependent)",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Healthy adult and paediatric controls","Subjects without kidney disease",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Heart failure patients with and without renal dysfunction","Heart failure patients (atrial fibrillation etc ...) with and without renal dysfunction",[13],[31],{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"Measuring sodium content","Sodium MRI measurement of sodium content in the tissues of all participants",[19,9,23,27,15],[36],{"name":37,"affiliation":38,"role":39},"Christopher W McIntyre, PhD, MD","Western University, Canada","PRINCIPAL_INVESTIGATOR",[41,46],{"name":37,"role":42,"phone":43,"phoneExt":44,"email":45},"CONTACT","519-685-8500","58502","christopher.mcintyre@lhsc.on.ca",{"name":47,"role":42,"phone":10,"phoneExt":10,"email":48},"Alireza Akbari, PhD","aakbari@uwo.ca",[50],{"facility":51,"status":52,"city":53,"state":54,"zip":10,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"LHSC Regional Renal Care Program","RECRUITING","London","Ontario","Canada","CA",{"type":58,"coordinates":59},"Point",[60,61],-81.23304,42.98339,{"lat":61,"lon":60},[64,67,68,70,72],{"name":65,"role":42,"phone":43,"phoneExt":44,"email":66},"Christopher W McIntyre, MD, PhD","christopher.mcintyre@lhsc.on.cas",{"name":47,"role":42,"phone":10,"phoneExt":10,"email":10},{"name":69,"role":42,"phone":10,"phoneExt":10,"email":10},"Guido Filler, MD",{"name":71,"role":42,"phone":10,"phoneExt":10,"email":10},"Jean Theberge, PhD",{"name":73,"role":42,"phone":10,"phoneExt":10,"email":10},"Timothy Scholl, PhD",{"type":75,"investigatorFullName":76,"investigatorTitle":77,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Chris McIntyre","Professor of Medicine, UWO","100286122","sodium-deposition-in-soft-tissues-of-patients-with-kidney-disease-100286122",false,"NCT03004547","Sodium Deposition in Soft Tissues of Patients with Kidney Disease","Evaluation of Sodium Deposition in Soft Tissues of Patients with Kidney Disease and Its Association with Patient Symptomatology","Inclusion Criteria:\n\n* Age greater than or equal to 6 years\n* For patients on maintenance hemodialysis or peritoneal dialysis: more than 3 months duration of therapy\n* For patients with CKD stage 1-5: CKD stage 1-5 and no indications to start dialysis\n* For heart failure patients: with or without renal dysfunction\n* For healthy controls: lack of kidney disease, heart failure, liver cirrhosis, and peripheral edema\n\nFor subsequent visits (must meet 1 of the below indicators):\n\n* Change in dialysis prescription\n* Change in renal replacement therapy modality\n* Change in medication\n* Parathyroidectomy\n* Intervention added to or removed from dialysis (i.e. such as but not limited exercise, cooling, and ischemic preconditioning)\n\nExclusion Criteria:\n\n* Pregnant, breastfeeding or intending pregnancy\n* Unable to give consent or understand written information\n* Contraindication to MRI study",true,"ALL","6 Years",{"count":89,"type":90},400,"ESTIMATED","OBSERVATIONAL","Sodium (Na+) hemostasis is abnormal in CKD patients, and this element can be deposited in the skin, muscle, and skeleton - to cope with long term sodium loading. It is known that sodium stored in this non-osmotically active way, is profoundly inflammatory. Furthermore, inflammation has been associated with several uremic symptoms. The investigators will use novel Na+ MRI imaging to examine the Na+ deposition in the skin, muscle, and skeleton of five groups:1) chronic in-center hemodialysis patients, 2) chronic peritoneal dialysis patients, 3) adult and paediatric patients with CKD stage 1-5 and 4) heart failure patients with and without renal dysfunction 5) sex and age-matched healthy adult and paediatric controls. Additionally, they will investigate the association between sodium deposition in these tissues with uremic symptomatology and biochemical markers of metabolism.",[94],"Haemodialysis Complication",[96,97],"Sodium","Soft Tissues","2025-02-10",{"date":100,"type":101},"2025-02-12","ACTUAL",{"date":103,"type":101},"2018-03-05",{"date":105,"type":90},"2026-02-28",{"name":76,"class":6},1]